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Small interfering RNA (siRNA)
Mesenchymal stem cellOrnithine decarboxylase (ODC) is the rate-limiting enzyme for polyamine biosynthesis. Suppression
of ODC by its irreversible inhibitor, a-diﬂuoromethylornithine (DFMO), or by RNA interference
through siRNA, enhanced osteogenic gene expression and alkaline phosphatase activity, and accel-
erated matrix mineralization of human bone marrow-derived mesenchymal stem cells (hBMSCs).
Besides, adipogenic gene expression and lipid accumulation was attenuated, indicating that the
enhanced osteogenesis was accompanied by down-regulation of adipogenesis when ODC was sup-
pressed. A decrease in the intracellular polyamine content of hBMSCs during osteogenic induction
was observed, suggesting that the level of endogenous polyamines is regulated during differentia-
tion of hBMSCs. This study elucidates the role of polyamine metabolism in the lineage commitment
of stem cells and provides a potential new indication for DFMO as bone-stimulating drug.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Ornithine decarboxylase (ODC) is the rate-limiting enzyme for
the biosynthetic pathway of polyamines, a series of low
molecular-weight polycations involved in various cellular pro-
cesses such as proliferation, differentiation, and apoptosis [1–4].
Because the level of polyamines and the activities of polyamine
biosynthetic enzymes are increased in tumor cells, ODC is one of
the potential targets for the development of anticancer drugs
[5,6]. Alpha-diﬂuoromethylornithine (DFMO), which is theirreversible inhibitor of ODC, suppresses cancer development in
animal models, and is being evaluated in clinical trials for the pre-
ventative treatment of colorectal cancer [7,8].
In addition to cancer cells, ODC and polyamine biosynthesis are
also important in the proliferation of several types of precursor
cells and stem cells. Recent studies indicate that the polyamine
metabolic pathway serves as a potential target for eliminating
breast cancer stem cells [9]. Earlier studies suggest that ODC is cru-
cial to the proliferation of neural progenitor cells and hematopoi-
etic precursor cells [10–12]. In rat bone-marrow stromal cells,
polyamine depletion by DFMO is suggested to reduce
TNFa/MG132-induced apoptosis and attenuate cell proliferation
[13]. Compared to the established role of ODC in promoting cell
proliferation, its function in cell differentiation is diverse and has
not been fully explored. Inhibition of ODC by DFMO prevents adi-
pocyte differentiation of 3T3-L1 cells [14,15]. However, DFMO
stimulates early cardiac commitment of mesenchymal stem cells
[16], as well as the differentiation of embryonal carcinoma cells
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active during hair follicle development and hair growth [23].
In our previous report, the mRNA level of ODC was reduced in
the presence of exogenous polyamines such as putrescine, sper-
midine and spermine, which enhance the osteogenic differentia-
tion of human bone marrow-derived stem cells (hBMSCs) [24]. It
is therefore hypothesized that suppression of ODC and thus deple-
tion of endogenous polyamines may be correlated with the osteo-
genic induction of hBMSCs. In this study, hBMSCs were treated
with DFMO as well as small interfering RNAs (siRNAs) designed
against ODC (siODC) to determine whether suppression of the
activity and mRNA expression of ODC alter the differentiation fate
of hBMSCs. These results may help to investigate the crosstalk
between pathways of osteogenesis and polyamine metabolism,
and determine whether the level of intracellular polyamines may
be manipulated to promote osteogenic differentiation.Fig. 1. Effect of DFMO and siODC on the viability of hBMSCs. Human BMSCs were
treated with osteogenic induction medium (OIM) or with various concentrations of
DFMO in OIM for 7 days. For siODC treatment, hBMSCs were cultured in various
concentrations of siODC for 2 days, followed by OIM for 7 days. Cell viability was
determined by WST-1 assay and expressed as optical density at 450 nm (OD450).
Error bars represent standard deviations (nP 3). *P < 0.05, compared to the control
(DMEM); #P < 0.05, compared to OIM.2. Methods
2.1. Cell culture
Human BMSCs (CD105+, CD166+, CD29+, CD44+, CD14, CD34
and CD45) were isolated from human bone marrow withdrawn
from the posterior iliac crest of the pelvic bone of normal volun-
teers, and were provided by Lonza, Basel, Switzerland. The cells
were cultured in mesenchymal stem cell medium (Lonza, Basel,
Switzerland) supplemented with Invitrogen MSC-Qualiﬁed Fetal
Bovine Serum (Life Technologies, Carlsbad, CA, USA), according to
the manufacturer’s instructions. Human BMSCs between passages
3 and 5 were used in this study. Cells were seeded at
3000 cells/well in 96-well plates for cell viability assay and alkaline
phosphatase (ALP) activity assay, at 104 cells/well in 24-well plates
for alizarin red S and oil red O staining, at 5  104 cells/well in
6-well plates for total RNA and protein extraction, and at
5000 cells/cm2 in 10-cm dishes for HPLC sample preparation.
Alizarin red S and oil red O staining were performed as previously
described [24].
2.2. DFMO treatment
For osteogenic differentiation studies, hBMSCs were treated
with 1, 10 or 100 lM DFMO in osteogenic induction medium
(OIM, 107 M dexamethasone, 10 mM b-glycerolphosphate and
50 mM L-ascorbate 2-phosphate in DMEM) 2 days after seeding,
and were cultured for another 7 or 14 days. For adipogenic differ-
entiation analysis, cells were cultured for 7 days after seeding to
reach 100% conﬂuence, which favor adipogenesis, before treated
with 1, 10 or 100 lM DFMO prepared in adipogenic induction
medium (AIM, DMEM supplemented with 1 lM dexamethasone,
0.5 mM isobutylmethylxanthine (IBMX), 10 lg insulin/ml and
100 lM indomethacin) or adipogenesis maintenance medium
(AMM, DMEM containing 10 lg/ml insulin). Cells were cultured
alternately in DFMO-supplemented AIM or AMM for another
14 days according to the instructions of Chemicon Mesenchymal
Stem Cell Adipogenesis kit (Millipore, Billerica, MA, USA).
2.3. siRNA transfection
Dharmacon siGENOME siRNA speciﬁc for human ODC (siODC),
as well as siGENOME GAPD Control siRNA (siMock) were designed
and synthesized by Thermo Scientiﬁc (Waltham, MA, USA).
Transfection of siRNA was carried out 24 h after hBMSCs were pla-
ted, using DharmaFECT 1 transfection reagent (Thermo Scientiﬁc,
Waltham, MA, USA) by following the manufacturer’s instructions.
The ﬁnal siRNA concentration was 3.1, 6.25 and 12.5 nmol/L. Twodays after siRNA transfection, cells were cultured in OIM for
another 7 to 14 days. For adipogenic induction, cells were main-
tained in DMEM for 7 days prior to siRNA transfection, and 48 h
after siRNA treatment, were incubated in adipogenesis-inducing
conditions for another 7 to 14 days.
2.4. Cell viability assay
Cell viability was analyzed by WST-1 assay using Quick Cell
Proliferation Colorimetric Assay Kit (BioVision, Milpitas, CA, USA)
and quantitated spectrophotometrically by measuring the optical
density at 450 nm, with a reference wavelength of 650 nm.
2.5. Alkaline phosphatase activity assay
The ALP activity of hBMSCs was determined by Alkaline
Phosphatase Fluorimetric Assay Kit (BioVision, Milpitas, CA, USA).
The kit utilizes the ﬂuorescent signal of 4-methylumbelliferone
(4-MU) produced by cleavage of the non-ﬂuorescent substrate,
4-methylumbelliferyl phosphate disodium salt (MUP), by the ALP
in cell lysates. Fluorescence intensity was determined at Ex/Em
360/440 nm, and the amount of 4-MU produced was quantiﬁed
using a standard curve produced by commercial ALP. ALP activity
was normalized to the total amount of protein and described as
the concentration of 4-MU (pmol/ml) produced per mg lysate per
minute.
2.6. Real-time polymerase chain reaction
Total RNA was isolated from hBMSCs by the RNeasy Mini Kit
(Qiagen, Germntown, MD, USA), and cDNA synthesis was carried
out using the SuperScript III First-Strand Synthesis SuperMix for
qRT-PCR (Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions. The cDNA was diluted to a ﬁnal con-
centration of 1 ng/ll and reacted with gene-speciﬁc primer pairs
and QuantiFast SYBR Green PCR Kit (Qiagen, Germntown, MD,
USA). Target genes were detected and ampliﬁed by Applied
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Sequence Detection Software V1.2 (Life Technologies, Carlsbad,
CA, USA). Primer sequences and conditions for real-time PCR anal-
ysis are the same as those reported previously [24].
2.7. Western blot analysis
Human BMSCs were harvested by Pierce RIPA buffer (Thermo
Scientiﬁc, Waltham, MA, USA) supplemented with 1 mM phenyl-
methanesulfonyl ﬂuoride (Sigma–Aldrich, St. Louis, MO, USA).
The crude extract was homogenized with a Branson S-450D
Soniﬁer (Emerson Industrial Automation, St. Louis, MO, USA), fol-
lowed by centrifugation at 14000g and 4 C for 15 min to remove
cell debris. A total of 50–70 lg of protein from each individual
sample was subjected to SDS–PAGE with a 4–12% gradient gel.
The resolved proteins were transferred to PVDF membrane using
the Trans-Blot Turbo Transfer System (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). The blots were incubated at room temperature
for 1 h in 3% bovine serum albumin, and reacted overnight at 4 C
with primary antibodies diluted in TBST buffer (50 mM Tris,
150 mM NaCl and 0.05% Tween 20, pH 7.5). After washing with
TBST buffer, the blots were reacted for 45 min with horseradish
peroxidase (HRP)-conjugated secondary antibodies diluted in
TBST at a ratio of 1:5000 (v:v). Chemiluminescent signals of targetFig. 2. Effect of DFMO and siODC on the expression of ODC and SSAT in hBMSCs during
induction medium (OIM) or adipogenic induction medium (AIM), or with various conc
cultured in various concentrations of siODC for 2 days, followed by OIM or AIM for 7 day
real-time PCR. Error bars represent standard deviations (nP 3). *P < 0.05 and **P < 0.01,proteins were produced with WesternBright ECL HRP substrate
(Advansta, Menlo Park, CA, USA) and detected with C-DiGit Blot
Scanner (LI-COR Biotechnology, Lincoln, NE, USA). Quantiﬁcation
of Western blot signals was performed with LI-COR Image Studio
4.0 software (LI-COR Biotechnology, Lincoln, NE, USA).
2.8. Analysis of intracellular polyamine content by high-performance
liquid chromatography (HPLC)
Human BMSCs were treated with 100 lM putrescine, 1 lM
spermidine, 1 lM spermine or 100 lM DFMO in OIM for 7 days.
The cells were lysed in 0.2 M perchloric acid, followed by addition
of 1,8-diaminooctane (DAO) to a ﬁnal concentration of 10 lM,
which serves as the internal standard. The polyamines in the cell
lysate were subjected to benzoylation and analyzed by an Agilent
Zorbax 300SB-C18 column (4.6  250 mm) in conjunction with
an Agilent 1100 Series HPLC System. Benzoylated polyamines were
eluted by a 20-min HPLC gradient program starting with metha-
nol–water (60:40, v/v) as reported in our previous study [25].
2.9. Statistical analysis
Statistical signiﬁcance relative to the control was analyzed
using one-way ANOVA followed by post hoc tests. Data set fromosteogenic and adipogenic induction. Human BMSCs were treated with osteogenic
entrations of DFMO in OIM or AIM for 7 days. For siODC treatment, hBMSCs were
s. Relative gene expression of (A and B) ODC and (C and D) SSAT was determined by
compared to the control (DMEM); #P < 0.05 and ##P < 0.01, compared to OIM.
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Levels of signiﬁcance were expressed as signiﬁcant, P < 0.05, and
highly signiﬁcant, P < 0.01, respectively.
3. Results
3.1. Effect of DFMO and siODC treatment on cell viability
When treated with DFMO or siODC, the viability of hBMSCs was
slightly decreased compared to the control and that incubated in
OIM, but was similar to that treated with siMock (Fig. 1). The num-
ber of viable cells decreased dramatically when hBMSCs were trea-
ted with 1 mM DFMO or 25 nM siRNAs (data not shown).
3.2. Effect of DFMO and siODC treatment on the mRNA level of ODC
and SSAT
The mRNA expression of ODC was suppressed 2 days after
siODC transfection (data not shown). After 7 days of osteogenic
or adipogenic induction, the mRNA level of ODC remained lower
in cells treated with DFMO and siODC, compared to that of the
OIM or AIM controls (Fig. 2A and B). On the other hand, the level
of spermidine/spermine N1-acetyl transferase (SSAT), the
rate-limiting enzyme of polyamine catabolism, increased uponFig. 3. Effect of DFMO and siODC on the osteogenic gene expression of hBMSCs. Hum
concentrations of DFMO in OIM for 7 days. For siODC treatment, hBMSCs were cultured
gene expression of (A) Runx2, (B) ALP, (C) osteocalcin and (D) osteopontin was determin
**P < 0.01, compared to the control (DMEM); #P < 0.05 and ##P < 0.01, compared to OIM.osteogenic and adipogenic induction, and treatment with DFMO
or siODC suppressed SSAT mRNA expression as well
(Fig. 2C and D). The decrease in SSAT expression of hBMSCs during
ODC suppression suggests that the enzyme may be regulated to
reduce excretion of intracellular polyamines, so as to maintain
polyamine homeostasis.
3.3. Effect of DFMO and siODC treatment on osteogenic gene
expression
Treatment of hBMSCs with DFMO resulted in up-regulation of
osteogenic genes such as Runt-related transcription factor 2
(Runx2), alkaline phosphatase (ALP), osteocalcin and osteopontin
(Fig. 3). Suppression of ODC by siODC also enhanced the expression
of early-onset osteogenic genes Runx2 and ALP (Fig. 3A and B), but
the increase in the mRNA level of osteocalcin and osteopontin was
less signiﬁcant under siODC treatment compared to that in the
presence of DFMO (Fig. 3C and D).
3.4. Effect of DFMO and siODC treatment on ALP activity and matrix
mineralization
ALP activity and matrix mineralization, both of which are mark-
ers for osteoblast maturation, were enhanced under DFMO oran BMSCs were treated with osteogenic induction medium (OIM) or with various
in various concentrations of siODC for 2 days, followed by OIM for 7 days. Relative
ed by real-time PCR. Error bars represent standard deviations (nP 3). *P < 0.05 and
Fig. 4. Effect of DFMO and siODC on the alkaline phosphatase (ALP) activity of
hBMSCs. Human BMSCs were treated with osteogenic induction medium (OIM) or
with various concentrations of DFMO in OIM for 7 days. For siODC treatment,
hBMSCs were cultured in various concentrations of siODC for 2 days, followed by
OIM for 7 days. Alkaline phosphatase activity was determined by Alkaline
Phosphatase Fluorimetric Assay Kit (BioVision, Milpitas, CA, USA) according to the
manufacturer’s instructions. Error bars represent standard deviations (nP 3).
**P < 0.01, compared to the control (DMEM); #P < 0.05 and ##P < 0.01, compared to
OIM.
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100 lM DFMO, or with 12.5 nM siODC, the ALP activity of
hBMSCs was higher than that cultured in OIM alone or treated with
siMock. The enhanced ALP activity coincided with the increase in
the mRNA level of ALP (Fig. 3B), indicating that suppression of
ODC is correlated with both the activity and mRNA expression of
ALP. Results from alizarin red S staining also suggest that ODC sup-
pression accelerated matrix mineralization of hBMSCs (Fig. 5A).
The amount of cell-bound alizarin red S (lM alizarin red S/lg
DNA) was increased to 1.55- or 1.24-fold, respectively, of thoseFig. 5. Effect of DFMO and siODC on matrix mineralization of hBMSCs. Human BMSCs we
of DFMO in OIM for 14 days. For siODC treatment, hBMSCs were cultured in various conce
with alizarin red S and observed with phase-contrast microscopy. (B) The concentration
normalized to the amount of DNA (lg). Error bars represent standard deviations (nP 3)
OIM.cultured in OIM or siMock in the presence of 100 lM DFMO or
12.5 nM siODC (Fig. 5B).
3.5. Effect of DFMO and siODC treatment on adipogenic gene
expression
During adipogenic differentiation, hBMSCs treated with AIM or
siMock had a signiﬁcantly higher mRNA level of adipogenic genes
such as peroxisome proliferator-activated receptor gamma
(PPARc), adipocyte protein 2 (aP2) and adipsin, compared to the
control (Fig. 6). When treated with DFMO or siODC, the expression
of adipogenic genes were signiﬁcantly suppressed, except for that
of aP2 in the presence of 3.1 and 6.25 nM siODC. These results indi-
cate that inhibition of the activity or mRNA expression of ODC
resulted in suppression of adipogenic differentiation.
3.6. Effect of DFMO and siODC treatment on lipid accumulation
Lipid accumulation, an indication of adipogenic terminal differ-
entiation, was increased in hBMSCs incubated under adipogenic
conditions, or treated with siMock, followed by adipogenic induc-
tion (Fig. 7). As expected, the amount of lipid droplets accumulated
in hBMSCs was signiﬁcantly reduced in DFMO- and siODC-treated
cells. The amount of lipid droplets decreased to around 0.6-fold or
less of AIM or siMock in the presence of DFMO or siODC. It is there-
fore suggested that the osteogenic activity of DFMO and siODC was
correlated with suppression of adipogenic terminal differentiation
as well as gene expression.
3.7. Effect of DFMO and siODC treatment on the expression of
transcription factors
We analyzed the protein expression of Runx2 and PPARc, the
key transcription factors related to osteogenic and adipogenic dif-
ferentiation, respectively, as well as that of Sp3, a transcription fac-
tor that antagonizes ODC and activates the liver/bone/kidney-type
ALP promoter [26,27]. As shown in Fig. 8A and B, treatment of
hBMSCs with DFMO or siODC resulted in a decrease in the protein
expression of ODC under both osteogenic and adipogenic condi-
tions. When hBMSCs were cultured in OIM alone, the expression
of Runx2 was increased compared to the control, but was similarre treated with osteogenic induction medium (OIM) or with various concentrations
ntrations of siODC for 2 days, followed by OIM for 14 days. (A) The cells were stained
of cell-bound alizarin red S was quantitated spectrophotometrically at OD570 and
. **P < 0.01, compared to the control (DMEM); #P < 0.05 and ##P < 0.01, compared to
Fig. 6. Effect of DFMO and siODC on the adipogenic gene expression of hBMSCs. Human BMSCs were cultured at high cell densities that favor adipogenesis, and treated with
AIM or with various concentrations of DFMO in AIM for 7 days. For siODC treatment, hBMSCs were cultured in various concentrations of siODC for 2 days, followed by AIM for
7 days. Relative gene expression of (A) PPARc, (B) aP2 and (C) adipsin was determined by real-time PCR. Error bars represent standard deviations (nP 3). **P < 0.01, compared
to the control (DMEM); #P < 0.05 and ##P < 0.01, compared to AIM.
Fig. 7. Effect of DFMO and siODC on lipid accumulation of hBMSCs. Human BMSCs were cultured at high cell densities that favor adipogenesis, and treated with DFMO under
adipogenic induction conditions as described in Section 2 for 14 days. For siODC treatment, hBMSCs were cultured in various concentrations of siODC for 2 days, followed by
adipogenic induction for 14 days. (A) Cells were stained with oil red O and observed with phase-contrast microscopy. (B) Cell-bound oil red O was extracted with isopropanol
and its intensity was determined colorimetrically at OD540. Error bars represent standard deviations (nP 3). **P < 0.01, compared to the control (DMEM); ##P < 0.01,
compared to AIM.
Y.-H. Tsai et al. / FEBS Letters 589 (2015) 2058–2065 2063to that of hBMSCs co-treated with DFMO or siODC, suggesting that
Runx2 may not be directly related to the osteogenic stimulation
resulted from ODC suppression (Fig. 8A). Nevertheless, we found
that the protein expression of Sp3 was up-regulated in the pres-
ence of DFMO or siODC under osteogenic conditions, but not when
hBMSCs was cultured in OIM alone or treated with siMock
(Fig. 8A), indicating that suppression of ODC may lead to activation
of ALP through the up-regulation of Sp3. On the other hand, the
expression of PPARc was suppressed in the presence of DFMO or
siODC and induced to differentiate adipogenically (Fig. 8B), consis-
tent with the results of PPARc mRNA expression in Fig. 6A.
3.8. Effect of exogenous polyamines and DFMO on intracellular
polyamine content
Treatment with OIM alone resulted in a decrease in the concen-
tration of all three of the common polyamines, including putres-
cine, spermidine, and spermine, suggesting that endogenous
polyamines may be associated with the regulation of stem cell dif-
ferentiation (Table 1). Compared to OIM, the total concentration of
intracellular polyamines was slightly increased in the presence of
100 lM putrescine. While 1 lM spermidine did not affect totalpolyamines, treatment with 1 lM spermine and 100 lM DFMO
decreased intracellular polyamines to levels lower than that of
OIM alone. It is known that exogenous polyamines may act
through pathways distinct from their endogenous counterparts
[28], but whether they were sequestered away in other pathways
or were simply exported from cells remains to be investigated.4. Discussion
Muscari et al. reported that matrix mineralization of rat BMSCs
was unaffected when incubated with 1 mM DFMO for 48 h, fol-
lowed by induction to differentiate in osteogenic medium for
3 weeks, indicating that polyamine depletion by DFMO does not
alter the differentiation potential of rat BMSCs [13]. However, we
found that the viability of hBMSCs reduced signiﬁcantly after trea-
ted with 1 mM DFMO in OIM for 7 days. Besides, when maintained
for 14 days in OIM supplemented with a lower concentration of
DFMO (100 lM), matrix mineralization of hBMSCs was enhanced
(Fig. 5). These results suggest that continuous suppression of
ODC during osteogenic induction may be critical in promoting
osteogenic terminal differentiation.
Fig. 8. Effect of DFMO and siODC on protein expression. Human BMSCs were treated with osteogenic induction medium (OIM) or adipogenic induction medium (AIM), or
with various concentrations of DFMO in OIM or AIM for 7 days. For siODC treatment, hBMSCs were cultured in various concentrations of siODC for 2 days, followed by OIM or
AIM for 7 days. Cells were harvested in RIPA buffer and subjected to Western blot analysis as described in Section 2. (A) Protein expression of ODC, Runx2, and Sp3 in hBMSCs
under osteogenic induction. (B) Protein expression of ODC and PPARc in hBMSCs under adipogenic induction. The ratios of Runx 2 and PPARc were determined by
normalizing the intensity of each band, determined by LI-COR Image Studio 4.0 software, to that of the control.
Table 1
Intracellular polyamine contents of hBMSCs treated with exogenous polyamines or DFMO in combination with OIM for 7 days.
Polyamines (nmol/mg) Control OIM 100 lM PUT/OIM 1 lM SPD/OIM 1 lM SPM/OIM 100 lM DFMO/OIM
Putrescine 43.91 ± 2.54 9.08 ± 3.13 16.28 ± 0.38 4.42 ± 0.54 3.21 ± 1.89 3.68 ± 1.01
Spermidine 16.55 ± 3.41 3.18 ± 0.36 5.21 ± 1.68 1.13 ± 0.24 4.29 ± 1.51 2.43 ± 0.26
Spermine 16.56 ± 2.35 8.30 ± 2.48 5.13 ± 1.95 15.05 ± 3.80 5.50 ± 0.03 4.26 ± 0.37
Total polyamines 77.01 ± 4.86 20.56 ± 4.01 26.62 ± 2.60 20.61 ± 3.85 13.01 ± 2.42 10.36 ± 1.11
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polyamines through the irreversible inhibition of ODC, a strategy
to block cancer cell proliferation [29], the effect of SSAT to counter-
act the effect of ODC suppression was seldom discussed, especially
when in this study, hBMSCs were treated with DFMO at concentra-
tions that did not affect cell viability (Fig. 1). By analyzing both the
catabolic and anabolic enzyme expression of polyamine biosynthe-
sis, it is suggested that in the presence of exogenous polyamines,
ODC was suppressed and SSAT was stimulated to prevent rapid
increase in intracellular polyamines [24]. Conversely, SSAT was
suppressed when hBMSCs were treated with DFMO or siODC pos-
sibly to prevent further depletion of the polyamine pool (Fig. 2C).
On the other hand, OIM had no effect on the mRNA expression of
ODC (Fig. 2A), but the expression of SSAT was increased (Fig. 2C),
which may explain the decrease in total polyamines (Table 1).
Similar increase in SSAT mRNA level was also observed in
goat-derived adipose stem cells induced to differentiateosteogenically with spermine and 1,25-dihydroxyvitamin-D3, but
their effect on ODC was not reported [30].
Studies on murine embryonal carcinoma cell lines demonstrate
that the level of intracellular polyamines must drop below certain
threshold to induce differentiation [18]. Indeed, total intracellular
polyamines were signiﬁcantly lowered when hBMSCs were cul-
tured under osteogenic conditions (Table 1). However,
co-treatment of hBMSCs with OIM and exogenous polyamines or
DFMO had limited effect on total polyamines compared to OIM
alone, suggesting that in addition to disrupting polyamine metabo-
lism, exogenous polyamines and DFMOmay act through additional
pathways to enhance osteogenic gene expression and terminal dif-
ferentiation. Our results from Western blot analysis indicate that
up-regulation of Sp3 by ODC suppression, together with the activa-
tion of Runx2 by osteogenic inducing agents in OIM (Fig. 8A),
enhanced ALP expression (Fig. 3B) and accelerated the osteogenic
differentiation of hBMSCs. However, the mechanism of how ODC
Y.-H. Tsai et al. / FEBS Letters 589 (2015) 2058–2065 2065inhibition led to suppression of PPARc remains to be investigated.
PPARc not only is the master regulator of adipocyte differentiation
[31], but also plays a role in the control of cell proliferation and
apoptosis, and is known to activate SSAT transcription [6,32]. The
mRNA levels of PPARc, ODC and SSAT, as well as polyamine levels
were signiﬁcantly higher in human colorectal carcinoma than in
normal tissue [33]. In hBMSCs, we demonstrate that a decrease
in the expression of PPARc, ODC and SSAT, accompanied by
reduced intracellular polyamines, was responsible for enhancing
osteogenesis. The fact that both ODC and PPARc are associated
with cell proliferation implicates that they may share common
effectors in the differentiation and proliferation of stem cells.
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